Galapagos NV

#4456

Rank

$1.75B

Marketcap

Belgium

Country

Leadership team

Mr. Bart Filius M.B.A., MBA (Pres, COO & Member of Management Board)

Dr. Andre Hoekema Ph.D. (Chief Bus. Officer & Member of Management Board)

Dr. Walid Abi-Saab (Chief Medical Officer & Member of Management Board)

Products/ Services

Biopharma, Biotechnology, Clinical Trials, Health Care, Medical

Number of Employees

1,000 - 20,000

Headquarters

Mechelen-bovelingen, Limburg, Belgium

Established

1999

Company Registration

SEC CIK number: 0001421876

Net Income

5M - 20M

Revenue

500M - 1B

Traded as

GLPG

Social Media

URL

https://www.glpg.com

Overview

Location

Recognition and Award

References

Summary

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

History

Galapagos Genomics NV was founded in 1999 as a joint venture between Crucell and Tibotec. The company later changed its name to Galapagos NV and completed its initial public offering on Euronext Amsterdam and Euronext Brussels in May 2005.The company uses a technological platform for its research, which is based on adenoviruses to introduce human gene sequences into a wide variety of human cell lines to knock-in or knock-down specific proteins.

In 2019, Gilead Sciences and Galapagos entered into transformative research and development collaboration. Gilead and Galapagos have also agreed to amend certain terms around the development and commercialization of filgotinib.In June 2022, the business announced it would acquire CellPoint for €125 million, with milestones of up to €100 million and AboundBio for $14million.

Mission

to develop innovative small molecule and antibody therapies to make a difference in the lives of patients.

Vision

To become a global leader in our field by delivering treatments that improve patient outcomes and make a meaningful difference in people's lives.

Key Team

Mr. Michele Manto M.B.A. (Chief Commercial Officer & Member of Management Board)

Ms. Sofie Van Gijsel (Head of Investor Relations)

Dr. Paulus A. Stoffels M.D., Ph.D. (CEO, Chairman & Member of Management Board)

Ms. Elizabeth Goodwin (VP of Investor Relations)

Marieke Vermeersch (Head of Corp. Communication)

John Montana (Managing Director of Argenta)

Ms. Chantal Tasset (Head of Devel.)

Recognition and Awards

Galapagos NV has won numerous awards over the years including the E&Y Entrepreneur Of The Year Award, Belgium's Most Awarded Life Sciences Company, FlandersBio Company of the Year and the EU Medical Device Award for Innovation. The company has also been recognised for its contribution to the fight against Covid-19.